J. vet. Pharmacol. Therap. 32, 577–584, doi: 10.1111/j.1365-2885.2009.01079.x.
Therapeutic efficacy of undenatured type-II collagen (UC-II) in comparison
to glucosamine and chondroitin in arthritic horses1
R. C. GUPTA*
T. D. CANERDY*
P. SKAGGS*
A. STOCKER*
G. ZYRKOWSKI*
R. BURKE*
K. WEGFORD*
J. T. GOAD*
K. ROHDE*
D. BARNETT*
W. D E WEES*
M. BAGCHI &
D. BAGCHI
*Murray State University,
Murray ⁄ Hopkinsville, KY; InterHealth
Research Center, Benicia, CA, USA
Gupta, R. C., Canerdy, T. D., Skaggs, P., Stocker, A., Zyrkowski, G., Burke, R.,
Wegford, K., Goad, J. T., Rohde, K., Barnett, D., DeWees, W., Bagchi, M.,
Bagchi, D. Therapeutic efficacy of undenatured type-II collagen (UC-II) in
comparison to glucosamine and chondroitin in arthritic horses. J. vet. Pharmacol. Therap. 32, 577–584.
The present investigation evaluated arthritic pain in horses receiving daily
placebo, undenatured type II collagen (UC-II) at 320, 480, or 640 mg
(providing 80, 120, and 160 mg active UC-II, respectively), and glucosamine
and chondroitin (5.4 and 1.8 g, respectively, bid for the first month, and
thereafter once daily) for 150 days. Horses were evaluated for overall pain, pain
upon limb manipulation, physical examination, and liver and kidney functions.
Evaluation of overall pain was based upon a consistent observation of all
subjects during a walk and a trot in the same pattern on the same surface. Pain
upon limb manipulation was conducted after the walk and trot. It consisted of
placing the affected joint in severe flexion for a period of 60 sec. The limb was
then placed to the ground and the animal trotted off. The response to the flexion
test was then noted with the first couple of strides the animal took. Flexion test
was consistent with determining clinically the degree of osteoarthritis in a joint.
Horses receiving placebo showed no change in arthritic condition, while those
receiving 320 or 480 or 640 mg UC-II exhibited significant reduction in
arthritic pain (P < 0.05). UC-II at 480 or 640 mg dose provided equal effects,
and therefore, 480 mg dose was considered optimal. With this dose, reduction
in overall pain was from 5.7 ± 0.42 (100%) to 0.7 ± 0.42 (12%); and in pain
upon limb manipulation from 2.35 ± 0.37 (100%) to 0.52 ± 0.18 (22%).
Although glucosamine and chondroitin treated group showed significant
(P < 0.05) reduction in pain compared with pretreated values, the efficacy was
less compared with that observed with UC-II. In fact, UC-II at 480 or 640 mg
dose was found to be more effective than glucosamine and chondroitin in
arthritic horses. Clinical condition (body weight, body temperature, respiration
rate, and pulse rate), and liver (bilirubin, GGT, and ALP) and kidney (BUN and
creatinine) functions remained unchanged, suggesting that these supplements
were well tolerated.
(Paper received 25 November 2008; accepted for publication 30 March 2009)
Ramesh C. Gupta, DVM, MVSc, PhD, DABT, FACT, FATS, Professor and Head,
Toxicology Department, Murray State University, Breathitt Veterinary Center, PO.
Box 2000; 715 North Drive, Hopkinsville, KY 42240, USA. E-mail:
ramesh1.gupta@murraystate.edu
1
Presented in part at the Annual Meeting of Eurotox, Amsterdam, September
10–12, 2007; American Academy of Veterinary Nutrition, San Antonio, TX,
June 3–5, 2008; and IXth World Conference on Clinical Pharmacology and
Therapeutics, Quebec City, Canada, July 27–August 1, 2008.
INTRODUCTION
Arthritis is a chronic debilitating disease that commonly inflicts
millions of horses around the world, because of excessive
2009 Blackwell Publishing Ltd
running and exercise, injury, immune disorder, aging, or genetic
predisposition (Ruggeiro, 2002). The two most common types of
arthritis are osteoarthritis and rheumatoid arthritis. In horses,
osteoarthritis occurs with a greater frequency than rheumatoid
577
578 R. C. Gupta et al.
arthritis or any other form of joint disease, like in humans and
dogs. Osteoarthritis is an inflammatory joint disease, which is
characterized by degeneration of the cartilage, hypertrophy of
bone at the margins, and changes in the synovial membrane and
fluid, which eventually leads to pain and stiffness of joints
(Goldring, 2000; Bellamy et al., 2001). This disease can wear
down cartilage in a joint to the point that bone rubs against
bone, resulting in loss of cartilage, and, in severe cases, cartilage
fragments can break off and irritate muscles with pain that are
adjacent to the bone. Chronic joint inflammation usually results
in progressive joint destruction, deformity, and loss of function
(van Roon et al., 2001).
Current therapy of arthritis relies upon nonsteroidal antiinflammatory drugs (NSAIDs) alone or in combination with
some other pain killers. Present treatments aim at alleviating
pain, control inflammation, and preserve ability to perform daily
functions. NSAIDs, which are cyclooxygenase (COX) inhibitors,
alleviate pain, but do not eliminate signs and symptoms of active
disease. In general, COX-II inhibitors (such as rofecoxib,
celecoxib, carprofen, and deracoxib) are considered safer than
nonspecific COX inhibitors (such as aspirin and ibuprofen). In
the recent past, chronic use of COX-II inhibitors has been
attributed to various side effects, including gastrointestinal (GI)
ulceration and bleeding, and hepatic, renal and cardiovascular
complications (Richardson, 1991; PDR, 2006; Infante & Lahita,
2000; Matteson, 2000; Schuna & Megeff, 2000; Matheson &
Figgilt, 2001; Lamarque, 2004; Solomon et al., 2004; Muhlfeld
& Floege, 2005). To our knowledge, such side effects have not
been reported in horses.
Presently, nutraceuticals are also used to ease the pain and
discomfort of arthritis in both humans and animals, including
horses (Trumble, 2005; Clegg et al., 2006; Bruyere & Reginster,
2007; Morva, 2007). These products are commonly used in
horses because they are administered orally, well tolerated and
considered safe. Nutraceuticals are defined as functional foods,
natural products, or parts of food that provide medicinal,
therapeutic, or health benefits, including the prevention or
treatment of disease. The present investigation utilized three
supplements (UC-II, glucosamine, and chondroitin), and their
brief description is provided here. Glycosylated undenatured
type-II collagen (UC-II) is derived from chicken sternum and
prepared under good manufacturing practices (GMPs), using low
temperature, which preserves its undenatured form and ensures
intact biological activity with active epitopes. Glucosamine,
extracted from crab, lobster, or shrimp shells, is an aminomonosaccharide precursor of the disaccharide unit of glycosaminoglycan, which is the building block of proteoglycans, the
ground substance of cartilage (Paroli et al., 1991). Chondroitin
sulfate, extracted from animal cartilage, such as tracheas and
shark cartilage, is a part of a large protein molecule (proteoglycan) that gives cartilage elasticity.
Currently, glucosamine and chondroitin are the two most
commonly used nutraceuticals in humans as well as in animals
(including dogs, cats, and horses), to alleviate pain associated
with arthritis (Dechant et al., 2005; Trumble, 2005). However,
based on recent randomized controlled trials and meta-analysis,
these supplements have shown only small-to-moderate symptomatic efficacy in human osteoarthritis (Bruyere & Reginster,
2007), although, this finding is still debated (Clegg et al., 2006;
Rozendaal et al., 2008). In our recent studies conducted in
dogs, daily administration of UC-II at 40 mg (providing 10 mg
active UC-II, respectively) daily dose for 120 days markedly
reduced arthritic pain (DeParle et al., 2005; D’Altilio et al.,
2007). Furthermore, our follow up studies also demonstrated
that UC-II (40 mg daily dose) in combination with other
nutraceuticals (glucosamine plus chondroitin) markedly
reduced the signs associated with arthritis in dogs, and thereby,
tremendously improved daily activity, as climbing stairs and
walking exercise. In a number of in vivo and in vitro
investigations, glucosamine and chondroitin have been found
very effective against osteoarthritis in horses (Fenton et al.,
2000, 2002; Dechant et al., 2005; Neil et al., 2005; Trumble,
2005). In brief, these studies suggested that the combination of
glucosamine and chondroitin appears to be more effective in
preventing or treating osteoarthritis in horses than either
product alone.
The present investigation was therefore undertaken with two
specific objectives: (i) to determine if daily administration of
active UC-II, or glucosamine plus chondroitin, can alleviate the
signs and symptoms of arthritis in horses and (ii) to determine if
these supplements are well tolerated and safe to administer for
the long term in arthritic horses.
MATERIALS AND METHODS
Animals
All horses used in this investigation were diagnosed with
osteoarthritis at the level of moderate severity. They were placed
at the equine center of Murray State University. During the
entire course of investigation, these horses were under the
supervision of licensed veterinarians. The protocol of the present
investigation for using arthritic horses and their treatment was
in compliance with the Murray State University Animal Use and
Care Guidelines. All animals were used routinely in their daily
workout schedule (riding classes). They were lodged into the
amount of time for daily workouts and rest periods. All animals
had the same workout protocol and rest time.
Criteria for inclusion into the study
From a large pool of horses located at the Murray State
University Equine Center, candidates were chosen based upon
outward visual signs of lameness. Once the lame candidates were
identified, the animals with evidence of osteoarthritis based upon
physical examination by two licensed veterinarians (Dr. Terry D.
Canerdy and Dr. William DeWees) were included in the study.
Evidence of osteoarthritis includes joint effusion in one or more
joints of the limbs, reduced joint flexibility, crepitation of the joint
on manipulation, and an increase in lameness upon flexion of
the affected joint.
2009 Blackwell Publishing Ltd
Horse arthritis treatment 579
Supplements
Glycosylated undenatured type-II collagen (UC-II), in the form of
capsules as a dietary supplement, was provided by InterHealth
Nutraceuticals, Inc. (Benicia, CA, USA). Similar to our previous
studies conducted in dogs, in the present investigation, the
undenatured form of glycosylated type-II collagen was used, as
this form of UC-II is found to be significantly more effective than
denatured type-II collagen against arthritis (Nagler-Anderson
et al., 1986; Bagchi et al., 2002). It should be noted that
undenatured type-II collagen can be denatured (hydrolyzed) by
chemical or high-temperature, altering its molecular structure
and integrity, and denatured collagen does not have active
epitopes rendering it inactive. Cosequin equine powder concentrate (glucosamine and chondroitin) was purchased from
Nutramax (Edgewood, MD, USA).
Experimental design and animal treatment
The present investigation was conducted on moderately osteoarthritic horses. In preliminary dose-dependent studies, horses
received UC-II at 80 or 160 mg (providing 20 and 40 mg active
UC-II, respectively) daily dose for a period of 150 days. Based on
this pilot dose-dependent study, the final investigation was
carried out on five groups of horses (n = 5–6) receiving placebo,
UC-II (higher doses), or glucosamine in combination with
chondroitin daily for 150 days. Group-I horses received placebo.
Horses in Group-II, -III, and -IV received UC-II at 320, 480, and
640 mg (providing 80, 120, and 160 mg active UC-II, respectively), accordingly. Group-V horses received glucosamine and
chondroitin (5.4 and 1.8 g ⁄ day, respectively, bid for the first
month, and once daily thereafter). Treatment in all five groups
was given daily (in the form of capsules administered orally in a
handful of grain) for a period of 5 months. While rationale for
selection of doses of UC-II was based on preliminary studies,
doses of glucosamine and chondroitin were based on the product
information provided on the insert along with Cosequin
(Nutramax).
following flexion. Flexion tests are commonly used in the equine
industry in determining the severity of a joint abnormality.
Scale used in pain measurement
The 0–10 global pain assessment was a scale used because it
provided a broad range of scale for pain. This scale was
consistently used throughout the investigation. In brief, 0, no
pain; 5, moderate pain; and 10, severe and constant pain. To our
knowledge, a universal scale does not exist to assess the pain.
For pain upon limb manipulation, results were graded on a
scale of 0–4: 0, no pain, 1, mild pain; 2, moderate pain; 3, severe
pain; and 4, severe and constant pain. The 0–4 scale was taken
from the American Association of Equine Practitioners (AAEP)
scorecard on lameness. They actually have 0–5, but category 5
was dropped because it indicates inability of an animal to move.
None of our subjects fit this category and therefore it was not
used.
Physical examination
Body weights and physical evaluation were also determined on a
monthly basis for 150 days. On a monthly basis horses were
evaluated for body weight, body temperature, and pulse rate.
Biochemical assays
Blood samples were collected by jugular venipuncture using
20-gauge needles and 12-cc syringes. Serum was separated in a
marble top tube (without anticoagulant) and transferred into
plastic snap-top tubes. Serum samples were frozen immediately
and kept at )80 C until analyzed for bilirubin, GGT, ALP,
blood urea nitrogen (BUN) and creatinine, using Beckman
Coulter CX5-PRO Synchron Clinical System (Fullerton, CA,
USA). Bilirubin, GGT, and ALP were used as markers of liver
function, and BUN and creatinine were used as markers of renal
function.
Statistical analysis
Pain assessment
The horses were evaluated for overall pain and pain after limb
manipulation, on a monthly basis for a period of 150 days.
Overall pain evaluation was based upon a consistent observation
of all subjects when the animal was at a walk and a trot. All
subjects were moved in the same pattern on the same surface
consistently. Gross pain measurement was done and recorded
during the horses movement trials.
Pain upon limb manipulation was conducted after the walk
and trot. It consisted of placing the affected joint in severe flexion
for a period of 60 sec. The limb was then placed to the ground
and the animal trotted off. The response to the flexion test was
then noted with the first couple of strides the animal took.
Flexion test was consistent with determining clinically the degree
of osteoarthritis in a joint. With an increase in osteophytes, the
animal has a degree of discomfort on movement of the limb
2009 Blackwell Publishing Ltd
The data of body weight in Table 1, serum chemistry in Table 2,
and pain measurement in Figs 1 & 2, are presented as means ±
SEM. Statistical significance of differences was determined by
ANOVA coupled with Tukey–Kramer test using the NCSS 2000
Statistical Software for Windows (Kaysville, UT, USA). Groups
were compared using Duncan’s Multiple-Comparison Test.
Differences with P < 0.05 were considered statistically significant.
RESULTS
Horses used in this investigation were diagnosed with osteoarthritis at a moderate severity. They exhibited some of the
common symptoms, such as difficulty during walking, stiffness
after periods of inactivity, swelling ⁄ tenderness in one or more
joints, steady pain in joints, and lameness.
580 R. C. Gupta et al.
Table 1. Effect of UC-II or Glucosamine plus Chondroitin on body weight (lbs) of horses
Day
0
30
60
90
120
150
Group-I placebo
1161
1172
1151
1131
1053
1080
±
±
±
±
±
±
40
16
48
43
28
39
(100)
(101)
(99)
(98)
(90)
(93)
Group-II 320 mg UC-II
1080
1070
1066
1068
1069
1082
±
±
±
±
±
±
18
23
22
21
17
23
Group-III 480 mg UC-II
(100)
(99)
(99)
(99)
(99)
(100)
1150
1147
1127
1137
1150
1102
±
±
±
±
±
±
59
58
53
56
66
59
Group-IV 640 mg UC-II
(100)
(100)
(98)
(99)
(100)
(96)
1190
1200
1164
1178
1203
1167
±
±
±
±
±
±
48
45
49
42
47
33
Group-V Gluc. + Chon.
(100)
(101)
(98)
(99)
(101)
(98)
1195
1204
1178
1185
1190
1195
±
±
±
±
±
±
30
27
33
34
31
49
(100)
(101)
(99)
(99)
(100)
(100)
Values are means ± SEM (n = 5–7). No significant change in body weight (P > 0.05). Numbers in parentheses are percent changes compared with
values of day 0 (100%).
Table 2. Effects of UC-II or glucosamine plus chondroitin on markers of liver and renal functions in serum of horses
Days
Parameters
Group
BIL (mg ⁄ dL)
I
II
III
IV
V
I
II
III
IV
V
I
II
III
IV
V
I
II
III
IV
V
I
II
III
IV
V
GGT (IU ⁄ L)
ALP (IU ⁄ L)
BUN (mg ⁄ dL)
Creatinine (mg ⁄ dL)
0
1.18
1.33
0.98
0.93
1.87
12.4
17.5
14.2
14.8
12.0
95.2
79.4
84.3
81.5
82.6
16.4
17.7
17.3
18.7
18.5
1.64
1.50
1.42
1.52
1.43
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
30
0.12
0.10
0.13
0.14
0.35
2.01
9.51
1.99
0.79
0.69
9.61
17.91
8.50
3.33
7.65
0.87
1.19
1.50
0.88
0.50
0.08
0.07
0.06
0.06
0.18
1.24
1.60
1.05
0.77
1.84
11.4
15.4
16.2
16.0
11.7
90.2
58.1
73.2
68.5
77.7
13.6
17.9
17.1
14.2
19.3
1.58
1.56
1.43
1.48
1.64
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
0.12
0.06
0.13
0.12
0.43
1.21
5.42
1.90
0.52
0.70
7.09
22.97
5.77
2.84
3.98
0.50
1.12
0.83
0.87
0.92
0.19
0.07
0.06
0.06
0.19
60
1.22
1.70
1.05
1.05
1.76
11.2
14.8
13.0
13.1
11.5
86.4
81.3
76.7
75.5
62.6
14.0
17.3
16.0
17.3
18.9
1.66
1.51
1.58
1.48
1.39
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
0.17
0.04
0.09
0.12
0.27
1.68
4.82
1.51
0.17
1.31
7.42
15.53
5.71
3.23
6.10
0.89
1.08
0.86
0.91
0.99
0.08
0.05
0.12
0.05
0.18
90
1.34
1.30
1.15
1.04
1.87
11.2
15.3
11.5
13.0
12.1
94.2
87.8
74.7
72.8
71.4
16.4
15.3
15.8
19.0
16.6
1.46
1.47
1.33
1.30
1.53
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
0.19
0.09
0.19
0.12
0.37
1.39
8.46
1.06
0.58
0.73
10.18
19.38
9.43
3.97
4.50
1.21
1.19
0.70
1.13
1.74
0.12
0.07
0.07
0.05
0.17
120
1.22
1.30
1.63
1.30
2.07
11.8
15.1
12.7
14.5
13.1
97.8
84.3
85.7
77.8
75.2
15.2
15.1
16.3
18.5
18.0
1.44
1.50
1.45
1.33
1.50
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
0.16
0.03
0.27
0.16
0.36
1.59
11.32
1.28
0.99
0.37
14.65
22.66
12.46
3.66
5.50
1.43
1.62
1.23
0.43
1.46
0.14
0.07
0.04
0.02
0.15
150
1.34
1.20
1.17
0.93
2.22
13.4
14.5
12.8
16.6
12.1
95.4
84.5
88.3
97.5
66.5
18.0
14.8
18.8
18.8
17.2
1.66
1.35
1.48
1.30
1.60
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
0.11
0.10
0.14
0.10
0.48
1.21
7.90
1.35
1.50
0.65
10.17
30.80
9.96
4.61
7.70
1.34
2.00
1.14
1.49
1.32
0.15
0.07
0.16
0.08
0.23
Values are means ± SEM (n = 5–7). No significant change in any parameter (P > 0.0.5).
All horses were grossly and physically examined and flexed for
lameness on a monthly basis for a period of 150 days. UC-II at a
320, 480, or 640 mg daily dose (providing 80, 120, or 160 mg
active UC-II, respectively) provided significant reductions in
arthritic pain by 60 days of treatment (Figs 1 & 2). In fact, with
higher daily dose of UC-II (480 or 640 mg), significant reduction
in overall pain was observed as early as after 30 days of
treatment. With UC-II (320 or 480 or 640 mg), horses showed
maximal pain reduction by 150 days of treatment (overall pain
reduction, 79%, 88%, and 91%, respectively; and pain after limb
manipulation, 71%, 78%, and 80%, respectively). After
5 months of UC-II treatment, the horses became very active,
and performed normally in their daily activities.
Horses receiving glucosamine (5.4 g) plus chondroitin
(1.8 g), bid for the first 30 days, and once daily, thereafter
for the next 120 days showed significant decrease in pain after
60 days of treatment (reduction in overall pain, 36%; and
reduction in pain after limb manipulation, 31%). Maximal
pain reduction was noted after 150 days of treatment (overall
pain, 68%; and pain after limb manipulation, 69%). On
comparison, the UC-II (480 or 640 mg daily dose) was found
to be approximately twice as effective as glucosamine plus
chondroitin, based on pain after limb manipulation on
day 90.
None of the horses in any group showed any adverse effects on
body weight (Table 1), hepatic (bilirubin, GGT, and ALP) or
renal (BUN and creatinine) function markers (Table 2), or body
temperature, pulse rate, and respiration rate (data not shown),
suggesting that these supplements are well tolerated by arthritic
horses and safe to administer for a long term.
2009 Blackwell Publishing Ltd
Horse arthritis treatment 581
Fig. 1. On a monthly basis, overall pain in
horses was measured as a general gross
observation and graded on a scale of 0–10: 0,
no pain; 5, moderate pain; and 10, severe and
constant pain. Values are mean ± SEM
(n = 5–7). * = Indicates significant difference
between the values of day 0 and posttreatment (P < 0.05).
Fig. 2. On a monthly basis, pain upon limb
manipulation was evaluated by animal’s pain
during the flexion of all four limbs for a min.
then jogged after each leg was flexed. Results
were graded on a scale of 0–4: 0, no pain;
1, mild pain; 2, moderate pain; 3, severe pain;
and 4, severe and constant pain. Values are
mean ± SEM (n = 5–7). *Significant difference between the values of day 0 and posttreatment (P < 0.05). **Significant difference
between the values of UC-II-treated and
glucosamine plus chondroitin-treated horses
(P < 0.05).
DISCUSSION
The present investigation evaluated therapeutic efficacy, tolerability, and safety of glycosylated undenatured type II collagen
(UC-II) and glucosamine and chondroitin in moderately arthritic
horses, following a long term of their use. The present findings
revealed that the therapy with UC-II at 320 or 480 or 640 mg
daily dose for a period of 5 months provided significant
improvement in ameliorating the overall pain and pain after
limb manipulation in arthritic horses. Although significant antiarthritic effects were noted after 60–90 days, the maximal
physical improvements were observed after 150 days of treatment and the horses were more playful and active (Figs 1 & 2).
2009 Blackwell Publishing Ltd
This suggests that prolonged treatment with these supplements
leads to better therapeutic results. Based on this study, it appears
that 480 mg daily dose of UC-II provides the best results, as at
further higher dose (640 mg providing 160 mg active UC-II),
UC-II offered therapeutic efficacy no greater than that observed
with 480 mg daily dose.
Like previous studies conducted in two monogastric species,
humans (Nagler-Anderson et al., 1986; Trentham et al., 1993,
2001; Barnett et al., 1996, 1998; Sieper et al., 1996; Trentham,
1998) and dogs (DeParle et al., 2005; D’Altilio et al., 2007), in
the horses, we used the undenatured form of UC-II. This form of
collagen with triple helix structure and active epitopes is found to
be significantly more effective than denatured form against
582 R. C. Gupta et al.
arthritis (Nagler-Anderson et al., 1986; Bagchi et al., 2002). In
none of the species has UC-II been found to produce any adverse
effects (Bagchi et al., 2002; D’Altilio et al., 2007), which
demonstrated that once UC-II is ingested, stomach acids and
enzymes perform a partial digestion of the collagen matrix,
resulting in chains of soluble collagen molecules of varying
length, containing biologically active epitopes. These structurally
precise natural epitopes in UC-II interact with Peyer’s Patches
and trigger the complex series of immunological events that, in
case of rheumatoid arthritis, down-regulates the body’s out-ofcontrol autoimmune response (Fig. 3) (Trentham et al., 2001;
Bagchi et al., 2002). In the case of osteoarthritis, which is often
characterized by a subclinical immune disorder and a vicious
cycle of inflammatory events, UC-II can promote a significant
reduction in inflammation (Bagchi et al., 2002). UC-II functions
through a process of oral tolerization that takes place in the
small intestine where the food is absorbed. Through a complex
series of immunological events, patches of lymphoid tissue
(Peyer’s Patches) surrounding the small intestine, screen
incoming compounds and serve as a ‘switch’ to turn the body’s
immune response to foreign substances on or off, depending
upon the substance. In dogs and humans, a small amount of
undenatured UC-II (10 mg active UC-II ⁄ day) taken orally has
been shown to turn off the immune response targeted at type-II
collagen in joint cartilage, and no adverse effects have been
noted (Trentham et al., 1993, 2001; Trentham, 1998; DeParle
et al., 2005). This immunization process helps the body to
differentiate between elements that are foreign invaders to the
body and those that are nutrients and are good for the body
(Weiner, 1997; Trentham, 1998). UC-II stops the immune
system from attacking and damaging its own joint cartilage,
thereby improving joint mobility and flexibility (Trentham et al.,
1993; Trentham, 1998; Bagchi et al., 2002). Type-II collagen is
one of the primary connective tissues of the body, providing
flexibility and support to bone joints. As UC-II is found to be as
equally effective in horses, as reported earlier in humans and
dogs, and it is presumed that the mechanisms described for
humans and dogs may also hold true for horses. Although the
precise biochemical mechanism involved in UC-II- induced
pharmacological anti-arthritic effects in humans, dogs or horses,
is not clearly established.
Glucosamine and chondroitin (5.4 and 1.8 g, respectively,
bid for the first 30 days, and once daily for the next 120 days)
significantly reduced arthritic pain by 60 days of treatment
(Figs 2 & 3), but maximal pain reduction was observed after
150 days (68% in overall pain and 69% in pain after limb
manipulation). Recently, a number of in vivo and in vitro studies
support the use of glucosamine and chondroitin in arthritic
horses (Fenton et al., 2000, 2002; Dechant et al., 2005; Neil
et al., 2005; Trumble, 2005). Unlike UC-II, glucosamine relieves
pain by enhancing proteoglycan synthesis, which is impaired in
osteoarthritic cartilage (Hougee et al., 2006). Chondroitin
sulfate aids in keeping cartilage tissue from dehydrating and
assists in cushioning impact stress and reducing joint pain.
Chondroitin sulfate is also believed to block certain enzymes
that result in the breakdown of cartilage. In an in vitro study,
Dechant et al. (2005) demonstrated that glucosamine plus
chondroitin: (i) reduced total glycosaminoglycan degradation,
which is involved in osteoarthritis and (ii) have no detrimental
effects on cartilage metabolism. Furthermore, from a series of
in vitro studies, Fenton et al. (2000, 2002) revealed that
glucosamine can prevent experimentally induced cartilage
degradation, and therefore support the use of this product in
prevention or treatment of cartilage loss in arthritic horses. In a
recent in vivo study, glucosamine and chondroitin ameliorated
arthritic pain in dogs, but comparatively UC-II was significantly
more effective. Similarly, in horses UC-II (480 or 640 mg daily
dose) was found to be more effective compared with glucosamine and chondroitin based upon limb manipulation on
90 days of treatment.
Aging - Stress - injury
Wear and tear
Acceleration of inflammation
Initiation of inflammation
Adhesion molecules
UC-II
UC-II deactivates killer T-cells
Pro-Inflammatory cytokines
Activate Killer T-Cells
Activate B-cells
Antibodies
Binding to antigens
Antibody-Tagged collagen (ATC)
Recruitment of macrophages to ATC
Collagenase secreted by macrophages
Breakdown of collagens by collagenase
Formation of Collagen-Debris
Removal of debris by macrophage
Erosion of joint collagen
Exposure of bones & bone crunching
Pain, Loss of mobility and flexibility
Osteoarthritis
Fig. 3. Mechanism of action of UC-II in
osteoarthritis.
2009 Blackwell Publishing Ltd
Horse arthritis treatment 583
In conclusion, daily administration of UC-II at varying doses
(320 or 460 or 640 mg) significantly reduced the signs and
symptoms of arthritis in horses. Daily administration of
glucosamine plus chondroitin also provided reduction in
arthritic pain, but the efficacy was less than UC-II. All three
supplements were well tolerated and did not produce any
adverse events.
ACKNOWLEDGMENT
This study was supported by InterHealth Nutraceuticals Inc.
(Benicia, CA, USA).
REFERENCES
Bagchi, D., Misner, B., Bagchi, M., Kothari, S.C., Downs, B.W., Fafard,
R.D. & Preuss, H.G. (2002) Effects of orally administered undenatured
type II collagen against arthritic inflammatory diseases: a mechanistic
exploration. International Journal of Clinical Pharmacology Research, 22,
101–110.
Barnett, M.L., Combitchi, D. & Trentham, D.E. (1996) A pilot trial of oral
type II collagen in the treatment of juvenile rheumatoid arthritis.
Arthritis and Rheumatism, 39, 623–628.
Barnett, M.L., Kremer, J.M., St. Clair, E.W., Clegg, D.O., Furst, D.,
Weisman, M., Fletcher, M.J.F., Chasan-Taber, S., Finger, E., Morales,
A., Le, C.H. & Trentham, D.E. (1998) Treatment of rheumatoid
arthritis with oral type II collagen: results of a multi-center, doubleblind, placebo-controlled trial. Arthritis and Rheumatism, 41, 290–297.
Bellamy, N., Carr, A., Dougados, M., Shea, B. & Wells, G. (2001) Towards
a definition of ‘‘differences’’ in osteoarthritis. Journal of Rheumatology,
28, 427–430.
Bruyere, O. & Reginster, J.Y. (2007) Glucosamine and chondroitin sulfate
as therapeutic agents for knee and hip osteoarthritis. Drugs and Aging,
24, 573–580.
Clegg, D.O., Reda, D.J., Harris, C.L., Klein, M.A., O’Dell, J.R., Hooper,
M.M., Bradley, J.D., Bingham, C.O. III, Weisman, M.H., Jackson, C.G.,
Lane, N.E., Cush, J.J., Moreland, L.W., Schumacher, H.R. Jr, Oddis,
C.V., Wolfe, F., Molitor, J.A., Yocum, D.E., Schnitzer, T.J., Furst, D.E.,
Sawitzke, A.D., Shi, H., Brandt, K.D., Moskowitz, R.W. & Williams, H.J.
(2006) Glucosamine, chondroitin sulfate, and the two in combination
for painful knee osteoarthritis. New England Journal of Medicine, 354
(8), 795–808.
D’Altilio, M., Peal, A., Alvey, M., Simms, C., Curtsinger, A., Gupta, R.C.,
Canerdy, T.D., Goad, J.T., Bagchi, M. & Bagchi, D. (2007) Therapeutic
efficacy and safety of undenatured type II collagen singly or in combination with glucosamine and chondroitin in arthritic dogs. Toxicology Mechanisms and Methods, 17, 189–196.
Dechant, J.E., Baxter, G.M., Frisble, D.D., Trotter, G.W. & McIlwraith,
C.W. (2005) Effects of glucosamine hydrochloride and chondroitin
sulfate, alone and in combination, on normal and interleukin-1
conditioned equine articular cartilage explants metabolism. Equine
Veterinary Journal, 37, 227–231.
DeParle, L.A., Gupta, R.C., Canerdy, T.D., Goad, J.T., D’Altilio, M.,
Bagchi, M. & Bagchi, D. (2005) Efficacy and safety of glycosylated
undenatured type II collagen (UC-II) in therapy of arthritic dogs.
Journal of Veterinary Pharmacology and Therapeutics, 28, 385–390.
Fenton, J.I., Chlebek-Brown, K.A., Peters, T.L., Caron, J.P. & Orth, M.W.
(2000) Glucosamine HCl reduces equine articular cartilage degradation in explants culture. Osteoarthritis and Cartilage, 8, 258–265.
2009 Blackwell Publishing Ltd
Fenton, J.I., Chlebek-Brown, K.A., Caron, J.P. & Orth, M.W. (2002) Effect
of glucosamine on interleukin-1-conditioned articular cartilage. Equine
Veterinary Journal. Supplement, 34, 219–223.
Goldring, M.B. (2000) Osteoarthritis and cartilage: the role of cytokines.
Current Rheumatology Reports, 2, 459–465.
Hougee, S., Hartog, A., Sanders, A., Graus, Y.M., Hoijer, M.A., Garssen,
J., Van Den Berg, W., Van Beuningen, H.M. & Smit, H.F. (2006) Oral
administration of the NADPH-oxidase inhibitor apocynin partially
restores diminished cartilage proteoglycan synthesis and reduces
inflammation in mice. European Journal of Pharmacology, 531, 264–
269.
Infante, R. & Lahita, R.G. (2000) Rheumatoid arthritis: new diseasemodifying and anti-inflammatory drugs. Geriatrics, 55, 30–32.
Lamarque, D. (2004) Safety of selective inhibitors of inducible cyclooxygenase-2 take a long period. Bulletin of Cancer, 91, S117–S124.
Matheson, A.J. & Figgilt, D.P. (2001) Rofecoxib: a review of its use in the
management of osteoarthritis, acute pain and rheumatoid arthritis.
Drugs, 61, 833–865.
Matteson, E.L. (2000) Current treatment strategies for rheumatoid
arthritis. Mayo Clinic Proceedings, 75, 69–74.
Morva, T. (2007) Glucosamine studies on horses. http: EzineArticles.com/?expert. pp. 1–3.
Muhlfeld, A.S. & Floege, J. (2005) COX-2 inhibitor induced anuric renal
failure in a previously healthy young woman. Clinical Nephrology, 63,
221–224.
Nagler-Anderson, C., Bober, L.A., Robinson, M.E., Siskind, G.W. &
Thorbecke, G.J. (1986) Suppression of type II collagen-induced
arthritis by intragastric administration of soluble type II collagen.
Proceedings of National Academy of Science (USA), 83, 7443–7446.
Neil, K.M., Orth, M.W., Coussens, P.M., Chan, P.S. & Caron, J.P. (2005)
Effects of glucosamine and chondroitin sulfate on mediators of
osteoarthritis in cultured equine chondrocytes stimulated by use of
recombinant equine interleukin-1beta. American Journal of Veterinary
Research, 66, 1861–1869.
Paroli, E., Antonilli, L. & Biffoni, M. (1991) A pharmacological approach
to glycosaminoglycans. Drugs Under Experimental and Clinical Research,
18, 335–343.
Physicians’ Desk Reference (PDR) (2006), 60nd edn. Thomson,
Montavale, NJ.
Richardson, D.W. (1991) Treatment of degenerative joint disease. Veterinary Review, 11, 210–212.
van Roon, J.A., Lafeber, F.P. & Bijlsma, J.W. (2001) Synergistic activities
of interleukin-4 and interleukin-10 in suppression of inflammation and
joint destruction of rheumatoid arthritis. Arthritis and Rheumatism, 44,
3–12.
Rozendaal, R.M., Koes, B.W., van Osch, G.V., Uitterlinden, E.J., Garling,
E.H., Willemsen, S.P., Zinai, A.Z., Verhaar, J.A., Weinans, H. & BiermaZeinstra, S.M. (2008) Effect of glucosamine sulfate on hip osteoarthritis. Annals of Internal Medicine, 148, 268–277.
Ruggeiro, B. (2002) Arthritis in horses. Essortment. October 22, 2005.
http://me.essortment.com/arthritisinho_rfgt.htm.
Schuna, A.A. & Megeff, C. (2000) New drugs for the treatment of
rheumatoid arthritis. American Journal of Health and Systematic Pharmacology, 57, 225–234.
Sieper, J., Kary, S., Sorenson, H., Alten, R., Effens, U., Huge, W., Hiepe, F.,
Kuhne, A., Listing, J., Ulbrich, N., Braun, J., Zink, A. & Mitchison, N.
(1996) Oral type II collagen treatment in early rheumatoid arthritis: a
double-blind, placebo-controlled, randomized trial. Arthritis Rheumatology, 39, 41–51.
Solomon, D.H., Schneeweiss, S., Glynn, R.J., Kiota, Y., Levin, R. &
Mogun, H.A.J. (2004) Relationship between selective cyclooxygenase-2 inhibitors and myocardial infarction in older adults. Circulation, 109, 2068–2073.
584 R. C. Gupta et al.
Trentham, D.E. (1998) Oral tolerization as a treatment of rheumatoid
arthritis. Rheumatic Diseases Clinics of North America, 24, 525–536.
Trentham, D.E., Dynesius-Trentham, R.A., Orav, E.J., Combitchi, D.,
Lorenzo, C., Sewell, K.L., Hafler, K.A. & Weiner, H.L. (1993) Effects of
oral administration of type II collagen on rheumatoid arthritis. Science,
261, 1727–1730.
Trentham, D.E., Halpner, A.D., Trentham, R.A., Bagchi, M., Kothari, S.,
Preuss, H.G. & Bagchi, D. (2001) Use of undenatured type II collagen
in the treatment of rheumatoid arthritis. Clinical Practice of Alternative
Medicine, 2, 254–259.
Trumble, T.N. (2005) The use of nutraceuticals for osteoarthritis in
horses. Veterinary Clinics of North America. Equine Practice, 21, 575–
597.
Weiner, H.L. (1997) Oral tolerance: immune mechanisms and treatment
of autoimmune diseases. Immunology Today, 18, 335–343.
2009 Blackwell Publishing Ltd